Recent Advances In Antibody Drug Conjugates – Mike Seganish (MSD, US) – talk was given by Stefan Symeonides (CDDF, UK) on behalf of Mike Seganish

Bispecific and their variants; T cell engagers – Ulrike Philippar (Johnson & Johnson, BE)

New Opportunities in Undruggable Targets Using TPD – Ian Churcher (Janus Drug Discovery, UK)

Access and basic principles of radiopharmaceuticals – Viktor Grünwald (University Hospital Essen, DE)

Advancements in Radiopharmaceutical and emerging guidance – Oliver Kiß (Helmholtz-Zentrum Dresden-Rossendorf, DE) – did not consent

From Bench to Bedside: Innovations in Radionuclide Therapy for Solid Tumors- The latest breakthroughs in radionuclide/ radiopharmaceutical treatments – Christophe Deroose (UZ Leuven, BE)

Short overview, including vector technology, types of antigens – Samra Turajlic (Francis Crick Institute; the Royal Marsden, UK) – did not consent

Individualized Neoantigen Therapy: The needle-to-needle process – Clemens Krepler (MSD, US)

Personalised treatments from regulatory perspective – Olga Kholmanskikh (FAMHP, BE) – did not consent

Cellular therapies and GMOs: What is out there and pipeline – Vladimir Galvao (Vall d’Hebron Institute of Oncology, ES)

Delivery of them: Learnings from CAR T cells – Tobias Menne (Newcastle University, UK)

15 years of ATMPs: EU regulatory framework – Caroline Pothet (EMA, NL)